▼ Daclizumab for MS

Abstract

▼Daclizumab (Zinbryta-Biogen Idec) is a new injectable disease-modifying drug licensed for the treatment of relapsing forms of multiple sclerosis (MS) in adults. It is a humanised monoclonal antibody that modulates interleukin-2 signalling. Here, we review the evidence on daclizumab and consider its place in the management of MS.